Fig. 1.

Study design. The identification period was from 1 December 2011 to 1 March 2020. The index event was the first pharmacy dispensing for rivaroxaban or warfarin during the identification period, while the index date was the first claim date for the initiation of rivaroxaban or warfarin. The baseline period was a 12-month period with continuous health plan enrollment prior to the index date. Criteria for inclusion in the 12-month baseline period could be met at any time during this period. BMI body mass index, NVAF nonvalvular atrial fibrillation, SE systemic embolism